Vicarious Surgical Board Seeks to Dissolve Company
The board of directors of Vicarious Surgical, a struggling surgical robotics developer, has asked shareholders to approve a plan to dissolve and liquidate the business. The proposal will be put to a vote at a special meeting on July 21, with results possibly announced the same day. If approved, the board intends to immediately cease all business operations except for winding up and liquidation.
The proposal requires a majority vote. According to a securities filing, Vicarious Surgical’s executives and directors collectively control shares representing 55% of total voting power, making approval likely.
Grim Outlook for Investors
In the filing, the board warned investors that “based upon our current outstanding liabilities, it is unlikely you will receive any distribution.” The company reported nearly $3.7 million in cash, cash equivalents, and short-term investments as of March 31, alongside $9 million in total liabilities and $12.6 million in assets. It lost $7.3 million in the first quarter of 2026, following losses of $50.2 million in 2025 and $63 million in 2024.
“We do not expect our cash and cash equivalents to be sufficient to continue as a going concern for any significant period of time,” the company stated. It noted that it has been unable to secure additional equity, debt, or other financing, and has failed to attract a buyer.
Liquidation Process and Asset Sale
With shareholder approval, the board will select an assignee to liquidate the soft-tissue robotics developer’s assets to settle outstanding obligations. The company emphasized that the process would not be a federal bankruptcy proceeding, stating that “the assignment and dissolution may present the best opportunity for recovery for our creditors.”
Surgical robotics expert Steve Bell flagged an auction of the company’s assets on LinkedIn, noting that “it looks like the end of the road for another interesting soft tissue robot.”
Executive Severance Packages
Three executives who also serve as board directors are entitled to significant severance payouts if terminated without cause or if they resign for good reason. CEO Stephen From would receive at least $500,000, co-founder and President Adam Sachs would receive at least $541,620, and Chief Technology Officer Sammy Khalifa would receive at least $318,600. All three would also receive outstanding equity awards, partial bonus payouts, and COBRA health care premium payments.
Those severance terms were part of executive employment contracts amended in the first quarter of 2026. Sachs and Khalifa alone held 54% of voting power as of June 10. Other major investors include co-founder Dr. Barry Greene (13%), Khosla Ventures (5%), and Gates Frontier (3%).
Company Operations and Workforce
As of March 9, Vicarious Surgical reported 26 employees: 11 in research and development, regulatory, and clinical; eight in manufacturing and quality assurance; and seven in marketing, sales, and administration. The company leases a 42,000-square-foot office at its Waltham, Massachusetts headquarters.
Since the filing, CFO Sarah Romano has tendered her resignation to take the same role at SS Innovations on Aug. 3. Company officials did not immediately respond to a request for comment.
The source for this article is https://www.therobotreport.com/vicarious-surgical-board-seeks-to-dissolve-company/.